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ABSTRACT 
Potassium channels are of paramount physiological and pathological importance and 
therefore, constitute significant drug targets. One of the keys to rationalize the way drugs 
modulate ion channels is to understand the ability of such small molecules to access their 
respective binding sites, from which they can exert an activating or inhibitory effect. Many 
computational studies have probed the energetics of ion permeation, and the mechanisms of 
voltage gating, but little is known about the role of fenestrations as possible mediators of 
drug entry in potassium channels. To explore the existence, structure and conformational 
dynamics of transmembrane fenestrations accessible by drugs in potassium channels, 
molecular dynamics simulation trajectories were analysed from three potassium channels: the 
open state voltage-gated channel Kv1.2, the G protein-gated inward rectifying channel 
GIRK2 (Kir3.2), and the human two-pore domain TWIK-1 (K2P1.1). The main results of this 
work were the identification of the sequence identity of four main lateral fenestrations of 
similar length and with bottleneck radius in the range of 0.9 to 2.4 Å for this set of potassium 
channels. It was found that the fenestrations in Kv1.2 and Kir3.2 remain closed to the passage 
of molecules larger than water. In contrast, in the TWIK-1 channel, both open and closed 
fenestrations are sampled throughout the simulation, with bottleneck radius shown to 
correlate with the random entry of lipid membrane molecules into the aperture of the 
fenestrations. Druggability scoring function analysis of the fenestration regions suggest that 
Kv and Kir channels studied are not druggable in practice due to steric constraining of the 
fenestration bottleneck. A high (>50%) fenestration sequence identity was found in each 
potassium channel subfamily studied, Kv1, Kir3 and K2P. Finally, the reported fenestration 
sequence of TWIK-1 compared favourably with another channel K2P channel TREK-2 
reported to possess open fenestrations, suggesting that K2P channels could be druggable via 
fenestrations, for which we reported atomistic detail of the fenestration region, including the 
flexible residues M260 and L264 that interact with POPC membrane in concerted fashion 
with the aperture and closure of the fenestrations.  
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INTRODUCTION 
The term ‘druggability’ refers to the ability of a small molecule to modulate the function of a 
target receptor protein. It is estimated that 10-15% of the genes identified by the Human 
Genome Sequencing Consortium constitute useful druggable targets, of which only half may 
constitute real protein targets.1 Due to their vast range of physiological roles, ion channels are 
of paramount pharmacological importance, and are targets for over 20% of drugs on the 
market.2 Potassium channel druggability mechanisms remains an active area of research, for 
which no single unified mechanism is known.3 Potassium channels form selective pores that 
span cell membranes, enabling the selective and rapid conduction of potassium ions down the 
electrochemical gradient.4 Their structure comprises two or four subunits, forming dimers of 
dimers or tetramers. A pore-loop structure lines the top of the pore, known as the selectivity 
filter that modulates the selective ion permeability. Currently, at least 60 unique potassium 
channel X-ray crystal structures are available,3 of which representatives of three families of 
potassium channels were considered here. 
The first channel employed in this study belongs to the voltage-gated (Kv) channel family 
which spans at least nine known subfamilies, Kv1-9.5 Small-molecule druggability of the 
Kv1 subfamily has been proposed to occur via a cooperative mechanism involving two main 
blocking sites: the inner-pore site, located below the selectivity filter, and a side-pocket 
cavity located between the pore and the voltage-sensor, for which it is thought fenestrations 
could play an active role in modulating the blockage mechanism.6-8 Current well-established 
inner-pore Kv1 blockers include 4-aminopyridine (4-AP), tetraethylammonium (TEA),9 
tetrabutylammonium (TBA),10 and correolide.11 Due to the highly conserved inner-pore 
sequence, these drugs do not show specificity among Kv1 subtypes, which has hindered 
further therapeutic applications. A new generation of phenoxyalkoxypsoralen derivatives has 
shown increased Kv1 subtype specificity, and holds therapeutic promise.12-13 Kv1.2 is an 
active druggable target for neurological and autoimmune disorders such as multiple sclerosis, 
type-1 diabetes mellitus and rheumatoid arthritis.12-13 
The second channel employed belongs to the inward-rectifying (Kir) channels, which 
preferentially conduct current in the inward direction into the cell. Kir channels constitute 
therapeutic target for many common disorders including hypertension, cardiac arrhythmia 
and pain.14 Kir channels span at least seven subfamilies, Kir1-7, with the Kir3 subfamily 
having their activity critically regulated by G protein-coupled receptors (GPCRs).15 Thus 
they are referred to as GPCR-activated Kir (GIRK) channels. The broad range of Kir-
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regulatory functions means that some Kir channels occupy a unique physiological ‘niche’.15 
Kir3.2 small-molecule druggability is currently limited to nonselective cardiovascular and 
neurological drugs with off-target activity toward Kir channels. This means that the real 
therapeutic potential and druggability of most Kir channels has not yet been determined 
experimentally.15 Current work on neuronal Kir3 (GIRK) pharmacology has focused on well-
studied neurological drugs, all of which exhibit low affinity toward GIRK, including the 
serotonin-reuptake inhibitor fluoxetine,15-16 as well as pore-blocking opiates, small-molecule 
analgesics for pain management. Crucially, a clear understanding of the potential of neutral 
GIRK channels in pain requires the development of selective Kir3.1/Kir3.2 small-molecule 
drugs.15 A mechanistic understanding of drug binding pathways and knowledge of specific 
chemical sequence of fenestrations may prove useful for this purpose. An example of a 
common small-molecule pore blocker, Vernakalant, reached clinical trials and showed 
efficacy in terminating the onset of atrial fibrillation. However, Vernakalant also inhibits the 
cardiac Kv1.5 and Kv4 channels by blocking the highly conserved Kv family pore, thus 
precluding further therapeutic assays.17  
The third and final channel studied belongs to the two pore domain potassium (K2P) 
channels, which generate leak potassium currents, and thus plays an essential role in cell 
excitability. K2P channels have been proposed to show weak inward rectification,18-19 
suggesting resemblance with/to inward-rectifying (Kir) potassium channels.19 Six 
subfamilies, TWIK, TREK, TALK, TASK, THIK, and TRESK have been identified, 
primarily implicated in a range of cardiovascular and neurological disorders. A unique 
structural attribute of K2P channels is the absence of the classical cytoplasmic bundle 
crossing rendering structural changes at the selectivity filter, the primary mode of gating.20-22 
The crystal structure of TWIK-1 helped elucidating the topology of the plasmatic membrane. 
A vast range of regulatory stimuli are proposed to modulate this gate,23 such as hydrophobic 
compounds and various lipids that readily enter the membrane bilayer through lateral 
fenestrations.24 Small molecule block of K2P channels is currently limited to the targeting of 
TREK-1. K2P channels are poorly inhibited by classical K+ channel blockers such as TEA, 
Cs+ and 4-aminopyridine when applied from the extracellular site, but it has recently been 
shown that a known family of Kv1 blockers, the quaternary ammonium (QA) ions, potently 
block TREK-1 when applied from the intracellular side.25 In Kv and Kir channels, QA ions 
are known to bind from the intracellular side by binding to a site deep within the pore just 
below the selectivity filter (the pore site). K2P block has been studied with spadin, a sortillin-
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derived peptide, which has been identified as a novel antidepressant treatment,26 but with no 
reported binding site. Sortillin binding has been reported to be akin to fluoxetine inhibition of 
TREK-1, which does not target the pore, but instead a C-terminal site.27 In addition, a series 
of substituted caffeate esters have been shown to relieve pain by targeting TREK-1, and 
therefore might contribute to the next generation of analgesic drugs.28  
To understand the mechanism of drug modulation of ion channels, it is necessary to 
understand the location of small molecule binding sites, and how they can be accessed. Drug 
binding depends both on the target conformational state (open, closed or inactivated), as well 
as the real-time dynamics of the residues lining the fenestrations and entry tunnels of the 
target. Many studies have probed the energetics of potassium ion permeation,29-32 and the 
mechanisms of gating,33-35 but little is known about the role and presence of fenestrations in 
potassium channels. Work on fenestrations in Kir1.1 channels found a specific cholesterol 
binding pocket accessible from the membrane via lateral fenestrations by docking studies.36 
Such a cavity was proposed to be absent in Kir2.2 and Kir3 from sequence alignment. 
Additionally, bound molecules were identified in the fenestration regions of the X-ray crystal 
structures of the TWIK-120 and TREK-2 (K2P10.1)37, specifically lipid density in TWIK-1 
fenestrations, and norfluoxetine (the active metabolite of Prozac) bound to TREK-2 
fenestrations. Comparison of TREK-2 structures in multiple activation states revealed distinct 
structural differences in the spatial attributes of fenestration regions, implicating ‘open’ 
fenestrations, and key residues within them, in the state-dependent block of TREK-2 by 
Prozac. 
In this work, we are utilizing the predictive power of computational modelling to characterize 
the fenestration regions in other potassium channels where crystal structures in several 
activation states are unknown, or the presence of fenestrations has not been examined in 
detail, in order to assess the accessibility, and hence potential druggability of such regions. 
The availability, topology and conformational dynamics of lateral fenestrations in the 
transmembrane domain of three potassium channels are studied using MD simulation 
trajectories comprising around one microsecond of accumulated sampling. The channels 
selected are, the voltage-gated potassium ion channel Kv1.2, the inward-rectifying GPCR-
activated Kir3.2 (GIRK2) channel, and the two-pore domain channel TWIK-1 (K2P1.1). The 
results are compared to the reported X-ray structure of TREK-2 in complex with 
norfluoxetine.37 The information reported may potentially aid in the design of next generation 
potassium channel blocking drugs. 
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METHODS 
Systems Set-up 
Molecular Dynamics (MD) simulations were carried out on the structure of open-state Kv1.2 
(PDB id 3LUT, resolution 2.9 Å),38 the close -and open states of the murine G protein-gated 
inward rectifying K+ channel GIRK2 (Kir3.2) (Kir3.2/C: PDB id 3SYA, resolution 2.98 Å,39 
and Kir3.2/O: PDB id 3SYQ, resolution of 3.44 Å,39 respectively) and of the open-state 
human two-pore domain potassium channel TWIK-1 (PDB id 3UKM, resolution 3.4 Å)20 
(Figure 1). The initial structure of missing the loops in Kir3.2/O (residues 70-80 or 67-81 in 
chains A or B respectively, and 118-133 in both chains) was generated using MODELLER 
9.11,40 and the crystal structure of the murine Kir3.2 solved in complex with the beta-gamma 
G protein subunits (PDB id: 4KFM) as template,41 as it contains the required loops. For 
TWIK1-1, residues 18-281 were used to for the structure of TWIK-1, and missing residues 
residues (95-99 and 169-174) were modelled using Modloop42 in MODELLER.  
The pore of each channel was initially hydrated by employing the SOLVATE software,43 
which facilitates the hydration of irregularly shaped solutes, particularly relevant in filling the 
central pore of the channels. The resulted system was then embedded in a pre-equilibrated 
lipid bilayer of 1-Palmitoy-l,2-oleoyl-sn-Glycero-3-phosphocholine (POPC) molecules, with 
the central pore axis aligned to the bilayer normal. Lipid molecules overlapping with protein 
atoms were removed. A rectangular box of dimensions specific to each system was used to 
centre the system, and the void space was filled with water molecules using the Solvate 
plugin of VMD, removing those overlapping with protein or lipid atoms. Potassium and 
chloride ions were added to the system to achieve neutralization up to a final concentration of 
150 mM to mimic a biological environment. Three potassium ions in the selectivity filter of 
the crystal structures were kept. In addition, in the case of Kir3.2/C, four sodium ions (one 
per subunit) present in the crystal structure were also included.  PIO ([(2R)-2- octanoyloxy-3-
[oxidanyl-[(1R,2R,3S,4R,5R,6S)-2,3,6-tris(oxidanyl)-4,5-diphosphonooxy- cyclohexyl]oxy- 
phosphoryl]oxy-propyl] octanoate) molecules present in both crystal structures of Kir3.2 
were used to reconstruct the PIP2 molecules proposed to bind in each state of the channel. 
The same stoichiometry as observed in the crystal structures was kept in the simulated 
systems, i.e. four and two PIP2 molecules for the close and open states, respectively. 
Recently developed CHARMM parameters for PIP2 were used.44 The CHARMM 36 force 
field45 was used for the lipids, CHARMM 2746 was used for the protein, the TIP3P model47 
was used for water, and the standard CHARMM parameters and NBFIXES were used for the 
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ions.48  
Molecular Dynamics simulations  
The NAMD2.949 software was used to perform the computations. Each system was subjected 
to 5,000 steps of energy minimization followed by a set of MD equilibration steps in the NpT 
ensemble including, using a 1 kcal/mol/Å2 force constant throughout: (i) 500 ps applying 
restraints on the protein, the water in the pore cavity, and the crystallographic potassium ions 
fixed to the crystal structure. The NAMD Tcl Forces module was used to avoid hydrating the 
void space in the hydrophobic interface between the channel transmembrane domain and the 
membrane by applying an inverse force on water molecules crossing the hydrophobic 
interface, thereby excluding them, while the lipids pack around the protein; (ii) 500 ps 
applying restraints on the protein backbone atoms, relaxing the solvent in the cavity and the 
amino-acid side chains; (iii) 500 ps applying restraints on the protein atoms; (iv) 500 ps 
applying restraints on the selectivity filter alone. Semi-isotropic pressure coupling at 1 atm 
was accomplished using the Nose-Hoover Langevin piston using a damping time constant of 
50 fs and a period of 200 fs, while temperature was maintained at 310 K by means of the 
Langevin thermostat with a damping coefficient of 1 ps-1. Long-range electrostatic 
interactions were treated using the particle mesh Ewald algorithm with a grid spacing of 1Å 
and van der Waals forces were smoothly switched off between 10-12 Å, NAMD defaults for 
spline and κ values.50 A Verlet neighbour list with pairlist distance of 13 Å was used. The 
lengths of covalent bonds involving hydrogen atoms were constrained by the SETTLE 
algorithm in order to use a 2-fs time-step. The multi time step algorithm Verlet-I/r-RESPA 
was used to integrate the equations of motion. Non-bonded short-range forces were computed 
every time step, while long-range electrostatic forces were updated every two time steps. The 
total available MD production runs amount to 0.8 µs. The Kir3.2/O trajectory was of 100 ns, 
the TWIK-1 trajectory of 200 ns, and the Kv1.2 trajectory of 400 ns. An additional 100 ns 
trajectory of Kir3.2 closed state (Kir3.2/C) was used to compare the Kir3.2/O result.  
  
Fenestration search 
The output of the MD simulation trajectories of each channel were scanned for fenestrations 
using the CAVER 3.0 software,51 in which the outer surface of the protein is calculated by 
rolling a large spherical probe around its surface, and then internal fenestrations are identified 
using a probe comprising 12 spheres of radius 0.8 Å. All identified fenestrations are then 
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grouped into clusters based on relative proximities and with an 8 Å cut-off for each cluster 
node. In this way, fenestrations differing from the node by more than 8 Å are excluded.  
Residues lining the fenestrations were compared using a multiple sequence alignment 
considering Kv1.2 (Uniprot P16389), Kv1.3 (Uniprot P22001), Kv1.5 (Uniprot P22460), 
Kv7.1 (Uniprot P51787), mammalian Kir3.2 (Uniprot P48542), Kir3.1 (Uniprot P48549), 
Kir2.2 (Uniprot Q14500), human TWIK-1 (TWIK-1; Uniprot O00180), K2P10 (TREK-2; 
Uniprot P57789) and K2P6.1 (TWIK-2; Uniprot Q9Y257) employing the ClustalO52 
algorithm. Electrostatic potential iso-surface calculations were performed using APBS v1.4,53 
with results presented in the Supplementary Material, Figures S3 and S4.  
Pfido druggability scoring function analysis 
The cavity analysis is a useful tool for obtaining specific residues and physical parameters 
about the dimensions of fenestrations, however, it does not provide a quantitative indication 
of the likelihood or druggability of fenestration sites, as quantified by e.g., the binding free-
energy at the site. Pfido54 is a relevant alternative method, which can yield a druggability 
score (kcal/mol) for each channel. Pfido is a druggability prediction method developed by 
Pfizer that aims to predict the druggability of pharmaceutical targets based solely on the 
binding-site structure. A Pfido calculation requires the definition of a binding site and a 
ligand probe. Norfluoxetine was chosen as the probe for these systems. The binding site was 
represented using computational geometry methods,55-56 and defined as the cavity spanned by 
fenestrations residues in a 5Å radial distance from the molecule probe origin. Three 
parameters were used to quantify the druggability of the binding: fraction lipophilic (non-
polar) surface area (SA), fenestration surface curvature and calculated druggability score. The 
calculated druggability score (kcal/mol) is the maximal affinity predicted (MAP) binding 
energy ∆GMAP, equation  (1), which is an estimate of the maximal achievable affinity for a 
binding pocket from a hit-to-lead optimization effort. 
    Equation (1) 
Here, γ(r) describes the solvent surface tension, and depends on the surface curvature. The 
curvature was estimated from a least squares fit (LSF) of a sphere to a surface patch. The 
total surface area of the pocket, SAtotal
t arget  is a normalization factor to the drug-like surface area 
SAdruglike
t arget size set to 300 Å2 (Table 2). The constant C accounts for the ligand desolvation free-
energy and assumes that the lipophilic surface area is constant. The fraction lipophilic surface 
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area is a direct measure of the ratio between the lipophilic surface area and the polar surface 
area (SAnp
target ) of the binding site, while the curvature gives a three-dimensional 
representation of the binding-site shape. The output druggability score ∆GMAP (kcal/mol) was 
converted to a nM affinity Kd value through equation (2) where R is the gas constant in units 
kcal/mol/K, and T is 298 K.  
Kd=exp(∆GMAP/RT)    Equation (2) 
The Pfido analysis was obtained for each potassium channel using five representative 
structures from the MD simulations chosen at intervals of 10 ns from the last 50 ns of 
simulation for each potassium channels, with the error estimates reported as one standard 
deviation (±σ). 
RESULTS AND DISCUSSION 
To establish the stability of the proteins during the simulation, changes in the backbone root-
mean-square deviation (RMSD) of each structure with respect to the crystal with time were 
calculated and shown in Figure S1. In all cases, the RMSD remains stable (<2 Å). In all three 
systems simulated, four clusters of lateral fenestrations were found and are illustrated in 
Figure 1.a,c and 2.a,b,c, with over  70% of analysed snapshots having fenestrations with 
bottleneck radius greater than the threshold 0.8 Å (Table 1). For each system the analysis was 
repeated at subsets of the whole trajectory length to show reproduction of the results obtained 
here were consistent over the timescales analysed. For Kv1.2, fenestration analysis was 
repeated for the first 100, 200 and 400 ns of simulation, yielding fenestration parameters 
within same standard deviation of statistical error (Supp. Mat. Table S3). For K2P, the 
available 200 ns trajectory was analysed for the first 100 and 200 ns, obtaining the same 
results (Supp. Mat. Table S4). 
In Kv1.2 the lateral fenestrations are formed at the interface of adjacent subunits, and can 
therefore be referred to as inter-chain tunnels. TWIK-1 is a structural homo-dimer, 
possessing a pseudo-tetrameric architecture, with two tunnels on the dimer interface (lateral-
A/B) and an additional set at the interface between individual domains (intra-subunit) within 
each subunit (lateral A and lateral B), in analogous positions to those in Kv1.2, yet displaying 
asymmetry between each subset. In Kir3.2, the lateral fenestrations correspond to pathways 
across individual subunits, also denoted intra-chain tunnels. Inter-chain fenestrations, similar 
to Kv1.2 and TWIK-1, are also found in Kir3.2, but with low populations (<40 %), 
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suggesting that they are less favourable in Kir3.2. Such lateral fenestrations are similar to 
what it is observed for Nav channels.57 Results indicate that, within each analysed channel, 
no significant differences between lateral fenestration lengths exist (Table 1). 
Fenestrations can be classified in two functional states depending on their bottleneck radius 
(BR): open and closed. In this work, an arbitrary cutoff of 1.6 Å was employed to 
discriminate between closed (BR<1.6 Å) and open (BR>1.6 Å) fenestrations. In all three 
systems simulated, the identified fenestrations proved stable with time. In the case of the 
simulations of Kv1.2 and Kir3.2, closed fenestration states with an average bottleneck radius 
of ~1 Å are sampled, with maximum values up to 1.6 Å (Figure 3.d,f). In the closed 
fenestration state, only transient (~1-2 ns) pore access is available for water-sized molecules.  
In the TWIK-1 X-ray crystal structure, the inter-chain fenestrations show bottleneck radii of 
2.5 Å. Upon simulation with this density removed, the fenestrations display average BR of 
1.4 ± 0.5 Å and 1.0 ± 0.2 respectively (Figure 2.i). The former fenestration is able to sample 
the open fenestration state (maximum opening of 2.5 Å), with the latter consistently in the 
closed state (BR of ~1 Å) resembling that in Kv1.2 and Kir3.2 (Figure 2.h,i). The values 
indicate that TWIK-1 fenestrations are mainly closed, as in Kv1.2 and Kir3.2, but they can 
spontaneously sample open states by adopting a BR close to that in the TWIK-1 X-ray 
structure.  
To study the characteristics of the bottlenecks in detail, the fenestration radius along the 
progression from the outside of the membrane to the inside toward the central pore was 
measured, and it is shown in Figure 4 for each analysed fenestration of Kv1.2, Kir3.2 and 
TWIK-1. One main constriction site is observed in all four lateral fenestrations. The 
reduction of the radius at that position is due to the presence of residues V399, I402 and 
A403 in Kv1.2, T105, E152, G180 and V183 in Kir3.2, and V139, I142, P143, F220, S224, 
M260, L264 in TWIK-1 (Supplementary Table S2 and Figure 4).  
The amino acid composition and sequence alignment of the main fenestration lining residues 
for Kv1.2, Kir3.2 and TWIK-1 is reported in Supplementary Table S2, the consensus set of 
contacts is illustrated in Figure 3.b,c,d, and the bottleneck-lining residues are illustrated in 
Figure 4.a,b,c. For Kv1.2, the lining residues are L328, I332, A397, V399, L400, T401, I402, 
A403, V406, P407, and V410 in each monomer (Figure 3.b). This path appears to be flanked 
with a higher content of hydrophobic (82%) than polar residues (18%). For Kir3.2 the main 
lining residues in each lateral fenestration are V188, N184, V183, G180, L179, T154, T153, 
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E152, W106, T105, V104, Y102 and V101 (Figure 3.c). The path in Kir3.2 appears more 
hydrophilic with 46% of hydrophobic residues, 46% of polar residues and 8% of negatively 
charged residues. For TWIK-1, the main lining residues for intra-subunit fenestrations 
(fenestrations 1 and 2) are S116, T117, T145, L146, L149, T225, L254 and L257, 
constituting 50% polar residues, while for inter-chain fenestrations (fenestrations 3 and 4) 
T117, V139, I142, L146, S224, T225, M260, L261 and L264, constituting 45% polar 
residues (Figure 3.d), with the remaining residues of both sets hydrophobic. The residues 
responsible for the equilibrium between open and closed fenestration states in TWIK-1 were 
identified as M260 and L264 (Figure 5.a,b,c,d), with a transition time on the order or 101 ns 
(Figure 5.f), meaning that MD simulations can adequately capture this side-chain movement 
on a 200 ns simulation scale. Fenestration accessibility for lipids was considered by 
occupancy density iso-surfaces (Figure S5), which reveal lipid density only around Kv1.2 
and Kir3.2 fenestrations on the iso-0.2 surface, without any lipid entry observed. For TWIK-
1, lipid penetration at the periphery of the inter-subunit (A/B) fenestrations (3,4) was 
observed (Figure 5.a,b). The lipid entry correlates with a bottleneck radius > 1.5 Å (Figure 
5.e compared to Figure 5.f).  
It was considered if a correlation exists between the channel activation state and fenestration 
opening. The open, activated Kv1.2 channel has only closed fenestrations, while the open, 
activated Kir3.2 channel state and the closed Kir3.2 channel states both possessed closed 
fenestrations. For TWIK-1, lipid penetration at the periphery of the inter-subunit (A/B) 
fenestrations (3,4) was observed (Figure 5.a,b), and the lipid entry correlates with a 
bottleneck radius > 1.5 Å (Figure 5.e compared to Figure 5.f). The bottleneck radius 
fluctuation correlates with the M260-L264 distance and the fenestration-lipid distance, as was 
shown in Figure 5.e compared to Figure 5.f. Channel conformational changes, in particular 
those responsible for the opening or closing processes, can affect the structure of the lateral 
fenestration and consequently, drug accessibility. This has been reported to depend on the 
channel type. In TREK-2, changes in functional state impacts the availability of the 
fenestrations.37 Comparison of TREK-2 structures in multiple activation states revealed 
distinct structural differences in the spatial attributes of fenestration regions, implicating 
‘open’ fenestrations, and key residues within them, in the state-dependent block of TREK-2 
by Prozac. Analysis of the fenestrations from MD simulations in both the open and closed 
states of Kir3.2 (Table 1) showed that both states possessed the four reported fenestrations 
with similar average and maximum bottleneck radii, as well as similar fenestration length, 
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suggesting that fenestrations are not state-dependent in this case. 
To supplement these results, a Pfido druggability analysis was performed on MD snapshots 
of the fenestration regions of Kv1.2, Kir3.2, TWIK-1 (Table 2), and compared to the crystal 
structure of TREK-2.This analysis revealed Kir3.2 fenestrations to be outliers, possessing 
half the magnitude of hydrophobic surface-area (165 ± 21 Å2) compared to the other channels 
(Kv1.2: 399 ± 28 Å2; TWIK-1: 387 ± 25 Å2; TREK-2: 401 Å2), with double the magnitude of 
polar surface area (122 ±15 Å2) compared to the other channels (Kv1.2: 42 ± 6 Å2; TWIK-1: 
30 ± 5 Å2; TREK-2: 85 Å2). This surface-area analysis was then complemented by an 
electrostatic potential (EP) iso-surface analysis of Kv1.2, Kir3.2 and TWIK-1 (Figure S3 and 
S4). The analysis revealed that Kv1.2 fenestrations containing 82% hydrophobic residues 
displayed their EP iso-surface uniformly around zero, while the Kir3.2 iso-surface showed 
the presence of polar lining residues in the fenestrations (N184 and Y102 in each 
fenestration). The Pfido analysis outputs a druggability score of magnitude < -10 kcal/mol for 
all channel fenestrations studied herein, with more negative score indicating greater 
druggable potential. By calculating Kd values and comparing to reference datasets of 
targets,54 it is possible to class the channels as potentially druggable, because with their nM 
affinity druggability scores Kd (Table 2) all range between 10
-3 to 38 nM, which according to 
data set comparisons ranks as druggable targets with Kd<100 nM.
54  
To understand the role of chemical sequence in fenestrations, a multiple sequence alignment 
was generated for mammalian Kv1.2, Kv1.3, Kv1.5, Kv7.1, Kir3.2, Kir3.1, Kir2.2, human 
TWIK-1, TREK-2 and TWIK-2(Figure 3.a). This reveals that the lining residues of the 
fenestrations in Kv1.2, Kir3.2 and TWIK-1 share a common region in the sequence, where 
residues T154 and T153 in Kir3.2 correspond to S224 and T225 in TWIK-1, or T280 and 
T281 in TREK-2; L179 in Kir3.2 is conserved as L400 in Kv1.2; G180 in Kir3.2 corresponds 
to T401 in Kv1.2; V183 in Kir3.2 is conserved as V262 in TWIK-1, while the latter is not a 
lining residue. Finally, N184 in Kir3.2 was not conserved, and corresponded to V263 in 
TWIK-1 and P405 in Kv1.2. In addition, the TWIK-1 fenestration bottleneck shares a 
common region with the sequence of TREK-2 (K2P10.1). The TREK-2 fenestration residues 
when binding norfluoxetine were reported to be I194, P198, C249, V253, V276, L279, T280, 
F316 and L320.37 Crucially, fenestration residues M260 and L264 in TWIK-1 correspond to 
fenestration residues F316 and L320 in TREK-2 as shown in Figure 3. This high similarity in 
fenestration bottleneck sequence could suggest that drugs targeting TREK-2 could also target 
TWIK-1, and that agonist/antagonist mechanisms of K2P channels could be similar. 
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Previous MD simulation studies reported the sequence conservation of fenestration-lining 
residues in sodium channels to be generally high,57 and claimed this to be higher than the 
reported low conservation in other ion channel families, including potassium channels, but 
did not distinguish between sequence identities among different sodium subfamilies. In this 
work, potassium channel sequence alignment found low global sequence conservation, with 
only ~4% of the transmembrane domains of mammalian Kv1.2, Kir3.2 and TWIK-1 
conserved, and a ~2% of local transmembrane fenestration sequence identity. However, 
potassium channel subfamilies display very high fenestration identities, 86% for Kv1 subtype 
members, 63% for Kir3 subfamily members, and 47% for the K2P1 subfamily members. 
While previous studies have claimed to find higher conservation in sodium channels, these 
they reported only Nav channel subfamily identities to be above 50%,57 which is not different 
from our reported sequence conservations. These higher identities thus suggest a common 
role for fenestrations in individual potassium channel subfamilies may be possible. This work 
has complemented earlier work on TREK-2,37 by identifying open fenestrations in  a second 
K2P channel, TWIK-1, and has concluded that the size of fenestrations renders this unlikely 
in Kv1.2 and Kir3.2 In this case, if the role of fenestrations in drug access is of secondary 
importance, it has been proposed that fenestrations bestow conformational flexibility on the 
pore domain, and thus play a role in gating.58 Previous studies on fenestrations in voltage-
gated sodium ion channels reported well-conserved fenestration-lining residues.59 
Links between fenestrations and druggability 
The blocking mechanism in Kv1.2 and Kv1.5 channels have been described as involving two 
primary binding sites: an inner pore site with sequence T…VIAV, and a non-pore site with 
sequence LLL...FIL...T,6, 8 with locations conserved across Kv1 and non-Kv1 members. In 
Kv1.2, the non-pore site is located in a voluminous side-pocket cavity delineated by residues 
L317 and L321 from the S4-S5 linker, F334, I337, and L341 from the S5 helix, and T401 
from S6 helix.8 In Kv1.5, the non-pore site is located in a cleft delineated by contacts L420, 
L423, L427, F440, I443, L447, and T507.6 In open-state Kv7.1, the non-pore site is located in 
a side-pocket of contacts L250, L251, and V254 in the S4-S5 linker, together with the phenyl 
ring of F351 from the S6 helix.60 The pore site alone is most likely unable to confer the acute 
selectivity of a given drug for different Kv channels, mainly because the sequence of the 
inner pore is conserved among Kv channels, as well as due to the vast chemical range of Kv 
inner-pore blockers, namely 4-AP, TEA,9 TBA,10 and correolide.11 It has been argued that 
selectivity for a given drug arises from a putatively allosteric or cooperative interplay 
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between the pore site and a side-pocket in Kv1.2,8 and Kv1.5.6 Psora-4 and PAP-1 of the 5-
phenylalkoxypsoralen family of drugs, designed to target autoimmune disorders12-13 were 
found to show Kv1 subtype specificity by cooperatively interacting with both the inner pore 
and the non-pore site.6, 8 The fenestration lining residues identified herein for Kv1.2 is 
partially in agreement with the residues constituting the Kv1 side-pocket, suggesting that the 
potential for cooperative interactions is a possibility. As suggested for the blocking 
mechanism in Kv1.3 and Kv1.5 (Psora-4 block),6, 13 and Kv2.1 (Flecainide and Propafenone 
block), the existence of lateral fenestrations connecting the pore and side-pocket sites might 
allow for allosteric interactions were the bottleneck radius larger.6, 8 The bottleneck radius 
sampled in the MD simulations revealed it to be too small to allow the aromatic ring of PAP-
1 to percolate from the side pocket to the inner pore. This suggests that the cooperative effect 
between the side-pocket and the inner pore pocket in Kv1.2 is more probable to be mediated 
by the protein residues lining the fenestrations than a result of direct contacts between drugs 
located in such pockets. Alternatively, conformational changes taking place in a time-scale 
not accessed by the MD simulations presented here could be responsible for widening the 
bottleneck of the lateral fenestrations. Similarly, for the Kir3.2 channel in both open and 
close conformations, the bottleneck radius sampled during the simulations corresponds only 
to closed fenestration states. On average, the size of the fenestration is too small to allow the 
entrance of even water molecules, except for very short time periods (1-2 ns) where 
maximum bottleneck radius of ~1.5 Å are observed. 
For TWIK-1 the inter-subunit fenestrations can sample an open fenestration state during the 
MD trajectory (Table 1), and additionally, the X-ray crystal structure of the ‘open state’ 
TWIK-1 is argued here to compare to the ‘down state’ of TREK-2,37 (Supporting Table S1 
and Figure 1.c,d) owing to its helical arrangement and the presence of such open inter-
subunit fenestrations. Both structures contained lipid density in the fenestrations, with TREK-
2 having the bound drug norfluoxetine in the fenestrations. However, TREK-2 fenestrations 
are only observed in the ‘down state’ (the putative closed or inactivated channel state).37 In 
the absence of norfluoxetine, the up-state conformation is adopted, and two hydrophobic 
residues, F316 and L320, occlude the fenestration as a consequence of the conformational 
transition. Thus, fenestration dynamics explains the state selective binding and action of 
norfluoxetine in TREK-2. In line with these observations, inter-subunit fenestrations in 
TWIK-1 predominantly adopt a closed conformation throughout the simulations, likely due 
to the removal of crystallised lipids during simulation setup. However, an inter-conversion 
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between closed (BR ~ 1.0 Å) and open (BR > 2.0 Å) fenestration states occurs throughout, 
providing ample opportunities for the entrance of lipid molecules and small drug compounds. 
This process appears to correlate with the extent of constriction between M260 and L264 
residues (Figure 5.c,d). The position of these residues is conserved with respect to TREK-2 
(F316 and L320), suggesting potential implications across the K2P family. 
The result found on the open state of TWIK-1 suggests that it behaves qualitatively like the 
up-state of TREK-2 with closed fenestration states, but that it is able to also sample the open 
fenestration states reported in the ‘down-state’ of TREK-2.37 Our results support the 
existence of a wide enough hydrophobic fenestration bottleneck in TWIK-1, which is mostly 
closed but can spontaneously open to allow for hydrophobic compounds to enter and either 
bind or access the pore via the lateral fenestrations.24 This could contribute to the 
understanding of how the TWIK-1 pore gate is modulated by a large range of regulatory 
stimuli and molecules, as suggested experimentally.23  
CONCLUSIONS 
In this study, MD simulation trajectories of three representative potassium channels have 
been used to investigate the presence and chemical characteristics and structural dynamics of 
lateral fenestrations, for which four fenestrations are identified in each channel. Additionally, 
over the time course of the simulations, no statistically significant fluctuations in fenestration 
length were recorded suggesting that transient fast protein side-chain motions and rotations 
do not appear to exert significant effects upon fenestration lengths. From bottleneck radius 
analyses, results indicate that the fenestrations in Kv1.2 and Kir3.2 could not modulate drug 
access (BR ~1.0 Å), while in the case of TWIK-1 (maximum BR of 2.5 Å), the fenestrations 
can potentially work as drug access pathways. It was shown that the rise in bottleneck radius 
correlates with the entry of lipid molecules into TWIK-1 fenestrations, which is then argued 
to be responsible for allowing TWIK-1 to sample both open and closed fenestrations. While 
our analysis shows Kv1.2 and Kir3.2 fenestrations to be closed, experiments have found Kv 
channel fenestrations to have the possibility of undergoing conformational rearrangements of 
lining residues to turn on the ability of binding drugs, with a recent X-ray crystal of KcsA 
containing the known Kv blocker QA ion bound in the fenestration region in the inter-subunit 
space, akin to the fenestrations 1-4 of Kv1.2 reported here, thus, the potential for druggable 
Kv1 and Kir3 targets can not be ruled out.61 The existence of slow transitions at timescales 
above 100 ns, which cannot be sampled with ns MD timescales suggests that the next step in 
fully mapping the significance of the Kv1 and Kir3 fenestration regions in perturbing protein 
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structure and function, 
TWIK-1 exhibited asymmetry in its fenestrations, with the side-chains of M260 and L264 
responsible for the channel sampling an equilibrium state between closed and open 
fenestration, with state lifetimes on the order of 101-102 ns. In the open state of TWIK-1, the 
fenestrations are mainly closed, but can also sample the open fenestration state. Because the 
reported fenestration sequence of TWIK-1 had overlap with that of TREK-2, including the 
identification of bottleneck residues M260 and L264 that are in correspondence with TREK-2 
fenestration residues F316 and L320, with the latter channel reported to possess open 
fenestrations, it is concluded that K2P channels could be druggable via fenestrations. We 
reported atomistic detail of the fenestration region, including the flexible residues M260 and 
L264 that interact with POPC membrane in concerted fashion with the aperture and closure 
of the fenestrations.  
In conclusion, the study identified four lateral fenestrations across the range of potassium 
channels studied. Using structural and sequence alignment, a detailed analysis was given of 
how these identified fenestrations differ among the K+-channel subtypes analysed. This 
information provides a framework for rationalizing the differential response of potassium 
channels to drugs targeting the transmembrane domain.  
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TABLES 
Table 1. Fenestration bottleneck features. Fenestration cluster ID (clustering threshold of 8 
Å), percentage of PDB snapshots analyzed with a bottleneck radius (BR) > 0.8 Å, 
fenestration type (intra or inter-chain), average (Av.) bottleneck radius (Å), maximum (max.) 
bottleneck radius (Å) and length of the fenestration (Å) are reported. Protein monomers are 
referred as A, B, C, and D. Open and closed ion channel states are indicated by O and C. 
Channel Cluster 
ID 
% snapshots 
BR > 0.8 Å 
Fenestration 
Type 
Av. BR 
(Å) 
Max. BR 
(Å) 
Length 
(Å) 
Kv1.2 
1 82 Lateral-A/D 1.0 ± 0.1 1.3 21 ± 4 
2 70 Lateral-B/C 1.0 ± 0.1 1.5 23 ± 4 
3 74 Lateral-A/C 1.0 ± 0.1 1.5 24 ± 3 
4 49 Lateral-B/D 0.9 ± 0.1 1.2 23 ± 4 
5 42 Lateral-A 1.3 ± 0.2 1.7 29 ± 6 
Kir3.2/O 
1 95 Lateral-B 1.0 ± 0.2 1.6 30 ± 3 
2 95 Lateral-D 1.0 ± 0.1 1.3 29 ± 3 
3 84 Lateral-A 1.0 ± 0.1 1.3 31 ± 3 
4 79 Lateral-C 1.0 ± 0.1 1.4 30 ± 3 
5 75 Lateral-C/D 0.9 ± 0.1 1.2 32 ± 3 
Kir3.2/C 
1 98 Lateral-D 1.0 ± 0.1 1.4 28 ± 2 
2 87 Lateral-C 1.0 ± 0.1 1.4 29 ± 3 
3 87 Lateral-B 0.9 ± 0.1 1.3 29 ± 3 
4 58 Lateral-A 0.9 ± 0.1 1.3 30 ± 3 
5 53 Lateral-B/C 0.9 ± 0.1 1.2 31 ± 5 
 
TWIK-1 
1 97 Lateral-A 1.2 ± 0.2 1.6 22 ± 2 
2 83 Lateral-B 0.9 ± 0.1 1.3 26 ± 2 
3 90 Lateral-A/B 1.4 ± 0.5 2.5 24 ± 2 
4 80 Lateral-A/B 1.0 ± 0.2 1.9 26 ± 4 
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Table 2. Pfido druggability analysis of fenestrations from MD snapshots of Kv1.2, 
Kir3.2, TWIK-1, compared to TREK-2 crystal structure. Individual Pfido components 
are: (a) Lipophilic Surface Area (SA; Å²) showing the total hydrophobic surface area of 
fenestration cavities, (b) Polar Surface Area (SA; Å²), (c) Total Surface Area (SA; Å²) which 
is the sum of hydrophobic and polar SAs, (d) Fraction of lipophilic SA, (e) Protein surface 
curvature, (f) Druggability score as a maximum affinity predicted (MAP) ∆GMAP (kcal/mol), 
(g) Druggability score as a dissociation constant (Kd). The results indicate that the channels 
are characterised by high lipophilic surface area (except Kir3.2 which has charged polar 
fenestration residues), low fenestration curvature and high druggability score for 
fenestrations. 
Protein 
SA (lipo)  
Å² 
SA (polar) 
Å² 
SA (total) 
Å² 
Fraction 
SA (lipo) 
Curvature 
Å 
Druggability 
∆GMAP 
(kcal/mol) 
 
Kd (nM) 
 
Kv1.2 399 ± 28 42 ± 6 441 ± 28 0.9 ± 0.0 6.2 ± 0.2 -15.8 ± 0.4 2.5x10-3 
Kir3.2 165 ± 21 122 ± 15 287 ± 15 0.6 ± 0.1 6.1 ± 0.2 -10.1 ± 0.9 38.4 
TWIK-1 387 ± 25 30 ± 5 417 ± 29 0.9 ± 0.0 6.1 ± 0.1 -16.3 ± 0.1 1.1x10-3 
TREK-2 401 85 486 0.8 6.1 -14.5 2.3x10-2 
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FIGURES 
Figure 1. Structures of the ion channels involved in this study. (a) Kv1.2, (b) Kir3.2, (c) 
TWIK-1, and (d) TREK-2 channel structures. Illustrations of the fenestrations found in the 
transmembrane domains of structures obtained from MD trajectories (d, e, f) and those 
observed in the crystal structure of TREK-2 (h). Chain A, B, C and D are in red, yellow, 
orange, and black. Fenestration clusters 1, 2 and 3 are in yellow, cyan, and orange 
respectively. Fenestration cluster 4 is in the rear view of each channel.  
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Figure 2. Lateral fenestrations and dynamics of the Bottleneck Radius (BR). Main lateral 
fenestrations oriented related to membrane plane, labelled and coloured by cluster ID, (a) 
Kv1.2 fenestrations 1 to 4, (b) Kir3.2/O fenestrations 1 to 5, and (c) TWIK-1 fenestrations 1 
to 4. Temporal evolution of the BR for each fenestration cluster is presented as a colour-map 
with radii values ranging from 0.0 Å (red) to 3.0 Å (green), is shown for (d) Kv1.2, (e) 
Kir3.2/O, and (f) TWIK-1.  
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Figure 3. Sequence and structural alignment. (a) Multiple sequence alignment of the 
human Kv1.2 (Uniprot P16389), Kv1.3 (Uniprot P22001), Kv1.5 (Uniprot P22460), Kv7.1 
(Uniprot P51787), mammalian Kir3.2 (Uniprot P48542), Kir3.1 (Uniprot P48549), Kir2.2 
(Uniprot Q14500), human TWIK-1 (Uniprot O00180), TREK-2 (Uniprot P57789) and 
TWIK-2 (K2P6.1; Uniprot Q9Y257) highlighting the regions where the bottleneck lining 
residues are located. Color code: Kv1.2 (red), Kir3.2 (blue), TWIK-1 (green), TREK-237 
(purple). Representative lining residues (>90% of each fenestration): (b) Kv1.2, (c) Kir3.2/O, 
and (d) TWIK-1 A/B lateral fenestration. 
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Figure 4. Fenestration dynamics as a function of time. (a, b, c) Radii spherical 
representation for fenestrations in Kv1.2, Kir3.2, and TWIK-1. Residues constituting the 
bottleneck are highlighted in licorice representation. (d,e,f) Evolution of fenestration 
bottleneck radii in Å, using a colour gradient ranging from 0 (blue) to 4 Å (red), during MD 
simulation of Kv1.2, Kir3.2/O, TWIK-1 respectively. The white gaps represent snapshots in 
which fenestrations with a probe radius > 0.8 Å threshold were not identified in the specific 
cluster. 
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Figure 5. TWIK-1 fenestrations. Lipid-protein interaction iso-0.2 surfaces for fenestrations 
measured as the density of lipid within a 4 Å cutoff criteria of the fenestration-lining residues 
of TWIK-1 for (a) fenestrations 3,4 (inter-chain) and (b) fenestrations 1,2 (intra-subunit). (c) 
TWIK-1 lipid-protein interaction contacts to residues M260 and L264, (e) Distance between 
POPC tail (C atom) and C-atom of side-chain of M260 (colour red) as a function of 
simulation time in the TWIK-1 system. (f) Distance between the C atoms of side-chains of 
M260 and L264 in the A/B inter-chain lateral fenestrations 3 and 4 as a function of 
simulation time in the TWIK-1 system. Fenestration values for 3 vary from open (distance > 
7 Å) to close (distance 4-5 Å). (g) Bottleneck radius for inter-chain fenestrations 3 (red) and 4 
(blue) over the course of the trajectory. Changes in the bottleneck size are correlated with the 
side-chain motion of M260 and L264.  
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